114 related articles for article (PubMed ID: 11715355)
1. Future perspectives and implications.
Sleight P
Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355
[TBL] [Abstract][Full Text] [Related]
2. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
3. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
[TBL] [Abstract][Full Text] [Related]
5. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
7. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
9. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
McQueen MJ; Lonn E; Gerstein HC; Bosch J; Yusuf S
Scand J Clin Lab Invest Suppl; 2005; 240():143-56. PubMed ID: 16112972
[TBL] [Abstract][Full Text] [Related]
10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
11. [The HOPE Study. What does it contribute to general practice?].
Mann J; Sleight P
MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
[TBL] [Abstract][Full Text] [Related]
12. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
[TBL] [Abstract][Full Text] [Related]
13. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
Pocanić D
Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
[TBL] [Abstract][Full Text] [Related]
14. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
15. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
17. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
18. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Boos CJ
Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
[TBL] [Abstract][Full Text] [Related]
20. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
